# Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

> **NCT05430399** · PHASE3 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 349 (estimated)

## Conditions studied

- Breast Neoplasms
- Locally Advanced or Metastatic Breast Cancer

## Interventions

- **DRUG:** utidelone
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT05430399
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-21
- **Primary completion:** 2025-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 349 (ESTIMATED)
- **Last updated:** 2023-07-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05430399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05430399, "Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05430399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*